Drug intelligence / Profile preview

SVT-22832

Development stage: Preclinical
Lead developer: Laboratorios Salvat
Modality: Hydrogel Systems → Drug Delivery Systems, Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intranasal

Overview

SVT-22832 is a moisturizing nasal spray developed by Laboratorios Salvat, utilizing a smart polymer formulation to provide relief for dry and irritated nasal passages. It is designed to form a protective barrier or film on the nasal mucosa, offering symptomatic relief for conditions such as the common cold, sinusitis, and allergies. The product is currently in the development phase and is characterized by its ease of use as a spray compared to other moisturizing formats. Its mechanism of action is primarily physical, acting as a moisturizing agent and barrier rather than a traditional pharmacological agent.

Beyond the preview

Go deeper on SVT-22832.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SVT-22832.

Explore the full profile